August 16, 2022

From the Co-Chairs, August 2022

President Biden to appoint Dr. Monica Bertagnolli as NCI Director; NCI-MATCH trial data leads to FDA drug approval
August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022

Trial Spotlight: Neha Vapiwala on the EA8191/INDICATE Study for Prostate Cancer

This phase III study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022

Institution Spotlight: Penn State Cancer Institute

A Standing Main Member of ECOG-ACRIN since 2002
August 16, 2022

News in Brief, August 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more